Search

Your search keyword '"Morace, A."' showing total 4 results
Start Over Author "Morace, A." Search Limiters Peer Reviewed Journal drugs
4 results on '"Morace, A."'

3. Anidulafungin, a new echinocandin: in vitro activity

Author

Elisa Borghi, Maria Teresa Montagna, Giulia Morace, and Roberta Iatta

Subjects
Aspergillus, Antifungal Agents, Echinocandin, biology, Antifungal drug, Fungi, Biological activity, Fungi imperfecti, Pharmacology, bacterial infections and mycoses, biology.organism_classification, Anidulafungin, In vitro, Microbiology, Echinocandins, Mycoses, Drug Resistance, Fungal, Biofilms, medicine, Animals, Humans, Pharmacology (medical), medicine.drug
Abstract

Anidulafungin is an antifungal drug belonging to the echinocandin class with a potent in vitro fungicidal activity against a wide range of Candida species, including C. glabrata and C. krusei. Anidulafungin is also active in vitro against moulds belonging to the genus Aspergillus and some dematiaceous genera. Furthermore, anidulafungin demonstrates in vitro activity against Candida spp. growing as biofilms. Resistance to anidulafungin remains very rare based on recent epidemiological data. Paradoxical or trailing effects should be considered in echinocandin susceptibility testing. The in vitro activity profile of anidulafungin makes it a useful addition to the Italian antifungal armamentarium.

Published
2009

4. Anidulafungin, a New Echinocandin: Effectiveness and Tolerability.

Author

Morace, Giulia, Borghi, Elisa, Iatta, Roberta, and Montagna, Maria Teresa

Subjects
*ANTIFUNGAL agents, *ASPERGILLOSIS treatment, *CANDIDIASIS treatment, *CLINICAL trials, *DRUG interactions, *DRUG side effects, *COMMUNICABLE disease treatment, *MYCOSES
Abstract

Anidulafungin is a new echinocandin with potent in vitro activity against Aspergillus and Candida species, including those resistant to fluconazole and amphotericin B. Results of several clinical trials indicate that anidulafungin is effective in treating oesophageal candidiasis, including azole-refractory disease. The results of a single randomized clinical trial comparing fluconazole and anidulafungin demonstrated that anidulafungin was noninferior to fluconazole in the treatment of candidaemia and invasive candidiasis. Studies evaluating the concomitant use of anidulafungin and either amphotericin B, voriconazole or ciclosporin did not demonstrate significant drug-drug interactions or adverse events. Anidulafungin appears to have an excellent safety profile: alterations of liver enzymes have been reported and slow infusion is recommended to prevent histamine-like reactions. On the basis of early clinical experience, it appears that anidulafungin will be a valuable option in the management of serious and difficult-to-treat fungal infections. [ABSTRACT FROM AUTHOR]

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results